50 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Article Searches
GSK (GSK) Increases Yet Falls Behind Market: What Investors Need to Know https://www.zacks.com/stock/news/2243108/gsk-gsk-increases-yet-falls-behind-market-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2243108 Mar 19, 2024 - In the most recent trading session, GSK (GSK) closed at $42.32, indicating a +0.43% shift from the previous trading day.
GSK (GSK) Stock Moves -0.09%: What You Should Know https://www.zacks.com/stock/news/2246352/gsk-gsk-stock-moves-0-09-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v3-2246352 Mar 26, 2024 - GSK (GSK) closed at $42.79 in the latest trading session, marking a -0.09% move from the prior day.
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092 Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960 Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth https://www.cnbc.com/2024/01/14/cancer-drugs-renewed-interest-in-adcs-will-continue-in-2024.html Jan 14, 2024 - The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.
GSK to sell 3.2% stake in spinoff Haleon: report https://seekingalpha.com/news/4055337-gsk-to-sell-stake-in-spinoff-haleon-report?source=feed_sector_healthcare Jan 16, 2024 - GSK (GSK) reportedly plans to sell a 3.2% stake in consumer healthcare products company Haleon (HLN), which it spun off in 2019. Read more here.
Watch GSK amid evidence hearing on Zantac litigation https://seekingalpha.com/news/4057520-watch-gsk-amid-hearing-on-zantac-litigation?source=feed_sector_healthcare Jan 23, 2024 - Investors should watch GSK amid a pre-trial hearing over litigation related to the heartburn medication Zantac, which could result in billions of...
GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth https://www.zacks.com/stock/news/2215035/gsk-gsk-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2215035 Jan 24, 2024 - Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store? https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142 Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
GSK Gears Up for Q4 Earnings: Will It Surpass Estimates? https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328 Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.

Pages: 12345

<<<Page 3>